Hansa Biopharma AB (publ)
HNSBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.10 | -0.37 | -0.29 |
| FCF Yield | -32.37% | -53.91% | -21.61% | -13.01% |
| EV / EBITDA | -4.30 | -2.18 | -2.95 | -5.76 |
| Quality | ||||
| ROIC | -115.86% | -112.04% | -41.24% | -64.48% |
| Gross Margin | 51.23% | 52.91% | 75.10% | 54.47% |
| Cash Conversion Ratio | 0.84 | 0.91 | 0.82 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.50% | 58.18% | 193.72% | 115.95% |
| Free Cash Flow Growth | 10.71% | -49.38% | -4.65% | -66.42% |
| Safety | ||||
| Net Debt / EBITDA | -1.05 | -0.19 | 1.27 | 1.14 |
| Interest Coverage | -3.41 | -7.47 | -13.48 | -788.15 |
| Efficiency | ||||
| Inventory Turnover | 32.01 | 41.73 | 39.54 | 63.74 |
| Cash Conversion Cycle | 158.82 | -279.58 | -481.96 | -1,137.00 |